Does the media prefer KYMR or STOK?

In the previous week, Kymera Therapeutics had 13 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Kymera Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.64 beat Kymera Therapeutics' score of -0.12 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or STOK?

In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 4 articles in the media. Protagonist Therapeutics' average media sentiment score of 1.09 beat Stoke Therapeutics' score of 0.64 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SYRE or STOK?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 9 mentions for Spyre Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.64 beat Spyre Therapeutics' score of 0.51 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STOK or IMVT?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Stoke Therapeutics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat Stoke Therapeutics' score of 0.64 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PCVX or STOK?

In the previous week, Vaxcyte had 11 more articles in the media than Stoke Therapeutics. MarketBeat recorded 15 mentions for Vaxcyte and 4 mentions for Stoke Therapeutics. Vaxcyte's average media sentiment score of 0.64 beat Stoke Therapeutics' score of 0.64 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Stoke Therapeutics (STOK) Competitors

$31.11 +0.14 (+0.45%)

As of 04:00 PM Eastern

Compare

STOK vs. KYMR, PTGX, SYRE, IMVT, and PCVX

Should you buy Stoke Therapeutics stock or one of its competitors? MarketBeat compares Stoke Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stoke Therapeutics include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Immunovant (IMVT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does Stoke Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Kymera Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Kymera Therapeutics currently has a consensus target price of $117.14, indicating a potential upside of 19.22%. Stoke Therapeutics has a consensus target price of $41.83, indicating a potential upside of 34.47%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Stoke Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	206.12	-$311.35M	-$3.57	N/A
Stoke Therapeutics	$184.42M	10.51	-$6.89M	-$2.81	N/A

Stoke Therapeutics has a net margin of -529.20% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

In the previous week, Kymera Therapeutics had 13 more articles in the media than Stoke Therapeutics. MarketBeat recorded 17 mentions for Kymera Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.64 beat Kymera Therapeutics' score of -0.12 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Protagonist Therapeutics presently has a consensus price target of $115.21, indicating a potential downside of 3.15%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 34.47%. Given Stoke Therapeutics' higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protagonist Therapeutics has a net margin of -154.88% compared to Stoke Therapeutics' net margin of -529.20%. Protagonist Therapeutics' return on equity of -17.76% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 4 articles in the media. Protagonist Therapeutics' average media sentiment score of 1.09 beat Stoke Therapeutics' score of 0.64 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	166.24	-$130.15M	-$1.81	N/A
Stoke Therapeutics	$184.42M	10.51	-$6.89M	-$2.81	N/A

Protagonist Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Stoke Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 9 mentions for Spyre Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.64 beat Spyre Therapeutics' score of 0.51 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,469.46	-$155.20M	-$2.08	N/A
Stoke Therapeutics	$184.42M	10.51	-$6.89M	-$2.81	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Spyre Therapeutics' return on equity of -42.88% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Spyre Therapeutics presently has a consensus price target of $95.83, suggesting a potential downside of 1.25%. Stoke Therapeutics has a consensus price target of $41.83, suggesting a potential upside of 34.47%. Given Stoke Therapeutics' higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Spyre Therapeutics beats Stoke Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Stoke Therapeutics compare to Immunovant?

Stoke Therapeutics (NASDAQ:STOK) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Stoke Therapeutics presently has a consensus target price of $41.83, suggesting a potential upside of 34.47%. Immunovant has a consensus target price of $37.33, suggesting a potential downside of 0.76%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Stoke Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.51	-$6.89M	-$2.81	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

In the previous week, Stoke Therapeutics had 2 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Stoke Therapeutics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat Stoke Therapeutics' score of 0.64 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Immunovant	N/A	-65.66%	-59.88%

Summary

Stoke Therapeutics beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 65.51%. Stoke Therapeutics has a consensus price target of $41.83, suggesting a potential upside of 34.47%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Stoke Therapeutics has higher revenue and earnings than Vaxcyte. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Stoke Therapeutics	$184.42M	10.51	-$6.89M	-$2.81	N/A

Vaxcyte has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Vaxcyte's return on equity of -32.51% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Vaxcyte had 11 more articles in the media than Stoke Therapeutics. MarketBeat recorded 15 mentions for Vaxcyte and 4 mentions for Stoke Therapeutics. Vaxcyte's average media sentiment score of 0.64 beat Stoke Therapeutics' score of 0.64 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vaxcyte beats Stoke Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STOK vs. The Competition

Export

Metric	Stoke Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.93B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-11.07	19.75	24.92	23.98
Price / Sales	10.51	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	5.04	8.29	10.79	6.50
Net Income	-$6.89M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.72%	5.21%	1.67%	-0.22%
1 Month Performance	6.03%	2.19%	0.43%	0.77%
1 Year Performance	168.42%	60.99%	32.84%	31.57%

Stoke Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STOK Stoke Therapeutics	2.5084 of 5 stars	$31.11 +0.5%	$41.83 +34.5%	+167.4%	$1.93B	$184.42M	N/A	100	High Trading Volume
KYMR Kymera Therapeutics	1.9089 of 5 stars	$85.59 -0.7%	$117.14 +36.9%	+116.8%	$7.09B	$39.21M	N/A	170	Trending News Insider Trade
PTGX Protagonist Therapeutics	1.2726 of 5 stars	$112.46 +2.4%	$115.21 +2.4%	+115.7%	$7.06B	$46.02M	N/A	120	Positive News
SYRE Spyre Therapeutics	1.1926 of 5 stars	$83.58 +3.5%	$92.50 +10.7%	+568.4%	$7.02B	$890K	N/A	73	Analyst Forecast Insider Trade Gap Down
IMVT Immunovant	1.7671 of 5 stars	$33.44 -0.5%	$37.33 +11.6%	+141.1%	$6.90B	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Competitors

STOK vs. KYMR, PTGX, SYRE, IMVT, and PCVX

How does Stoke Therapeutics compare to Kymera Therapeutics?

Summary

How does Stoke Therapeutics compare to Protagonist Therapeutics?

Summary

How does Stoke Therapeutics compare to Spyre Therapeutics?

Summary

How does Stoke Therapeutics compare to Immunovant?

Summary

How does Stoke Therapeutics compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Competitors

STOK vs. KYMR, PTGX, SYRE, IMVT, and PCVX

How does Stoke Therapeutics compare to Kymera Therapeutics?

Which has more volatility and risk, KYMR or STOK?

Do analysts rate KYMR or STOK?

Which has better earnings and valuation, KYMR or STOK?

Is KYMR or STOK more profitable?

Does the media prefer KYMR or STOK?

Summary

How does Stoke Therapeutics compare to Protagonist Therapeutics?

Do analysts prefer PTGX or STOK?

Do insiders & institutionals have more ownership in PTGX or STOK?

Is PTGX or STOK more profitable?

Does the media prefer PTGX or STOK?

Which has stronger earnings and valuation, PTGX or STOK?

Which has more volatility & risk, PTGX or STOK?

Summary

How does Stoke Therapeutics compare to Spyre Therapeutics?

Does the media prefer SYRE or STOK?

Which has better valuation & earnings, SYRE or STOK?

Is SYRE or STOK more profitable?

Do institutionals and insiders hold more shares of SYRE or STOK?

Which has more volatility & risk, SYRE or STOK?

Do analysts rate SYRE or STOK?

Summary

How does Stoke Therapeutics compare to Immunovant?

Do analysts prefer STOK or IMVT?

Which has preferable valuation & earnings, STOK or IMVT?

Does the media refer more to STOK or IMVT?

Which has more volatility & risk, STOK or IMVT?

Do institutionals and insiders believe in STOK or IMVT?

Is STOK or IMVT more profitable?

Summary

How does Stoke Therapeutics compare to Vaxcyte?

Do analysts recommend PCVX or STOK?

Which has better earnings & valuation, PCVX or STOK?

Is PCVX or STOK more profitable?

Which has more volatility and risk, PCVX or STOK?

Do institutionals and insiders hold more shares of PCVX or STOK?

Does the media prefer PCVX or STOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools